6/7
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5/29
04:30 pm
oric
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
5/28
10:02 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
5/7
02:23 pm
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at Citigroup Inc. from $15.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at Citigroup Inc. from $15.00 to $14.00. They now have a "buy" rating on the stock.
5/6
04:10 pm
oric
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]
5/6
04:05 pm
oric
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
Low
Report
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
5/3
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/15
04:34 pm
oric
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC [Yahoo! Finance]
4/15
04:15 pm
oric
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Low
Report
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
4/8
08:14 am
oric
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Medium
Report
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
4/8
08:00 am
oric
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/5
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/4
04:33 pm
oric
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
4/4
04:30 pm
oric
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
3/29
05:40 am
oric
ORIC Pharmaceuticals: Rally Seems Overdone [Seeking Alpha]
Medium
Report
ORIC Pharmaceuticals: Rally Seems Overdone [Seeking Alpha]
3/27
10:56 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at JPMorgan Chase & Co. from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at JPMorgan Chase & Co. from $19.00 to $18.00. They now have an "overweight" rating on the stock.
3/21
08:06 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at HC Wainwright from $15.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at HC Wainwright from $15.00 to $21.00. They now have a "buy" rating on the stock.